137 related articles for article (PubMed ID: 16702327)
1. CYP17 genotype modifies the association between lignan supply and premenopausal breast cancer risk in humans.
Piller R; Verla-Tebit E; Wang-Gohrke S; Linseisen J; Chang-Claude J
J Nutr; 2006 Jun; 136(6):1596-603. PubMed ID: 16702327
[TBL] [Abstract][Full Text] [Related]
2. The risk of breast cancer associated with dietary lignans differs by CYP17 genotype in women.
McCann SE; Moysich KB; Freudenheim JL; Ambrosone CB; Shields PG
J Nutr; 2002 Oct; 132(10):3036-41. PubMed ID: 12368392
[TBL] [Abstract][Full Text] [Related]
3. Plasma enterolactone and genistein and the risk of premenopausal breast cancer.
Piller R; Chang-Claude J; Linseisen J
Eur J Cancer Prev; 2006 Jun; 15(3):225-32. PubMed ID: 16679865
[TBL] [Abstract][Full Text] [Related]
4. CYP17 5'-UTR MspA1 polymorphism and the risk of premenopausal breast cancer in a German population-based case-control study.
Verla-Tebit E; Wang-Gohrke S; Chang-Claude J
Breast Cancer Res; 2005; 7(4):R455-64. PubMed ID: 15987450
[TBL] [Abstract][Full Text] [Related]
5. Dietary phytoestrogen intake and premenopausal breast cancer risk in a German case-control study.
Linseisen J; Piller R; Hermann S; Chang-Claude J;
Int J Cancer; 2004 Jun; 110(2):284-90. PubMed ID: 15069695
[TBL] [Abstract][Full Text] [Related]
6. Plasma enterolactone and breast cancer risk in the Nurses' Health Study II.
Xie J; Tworoger SS; Franke AA; Terry KL; Rice MS; Rosner BA; Willett WC; Hankinson SE; Eliassen AH
Breast Cancer Res Treat; 2013 Jun; 139(3):801-9. PubMed ID: 23760859
[TBL] [Abstract][Full Text] [Related]
7. The CYP17 MspA1 polymorphism and breast cancer risk: a meta-analysis.
Ye Z; Parry JM
Mutagenesis; 2002 Mar; 17(2):119-26. PubMed ID: 11880540
[TBL] [Abstract][Full Text] [Related]
8. The relationship between a polymorphism in CYP17 with plasma hormone levels and breast cancer.
Haiman CA; Hankinson SE; Spiegelman D; Colditz GA; Willett WC; Speizer FE; Kelsey KT; Hunter DJ
Cancer Res; 1999 Mar; 59(5):1015-20. PubMed ID: 10070957
[TBL] [Abstract][Full Text] [Related]
9. Serum enterolactone and risk of breast cancer: a case-control study in eastern Finland.
Pietinen P; Stumpf K; Männistö S; Kataja V; Uusitupa M; Adlercreutz H
Cancer Epidemiol Biomarkers Prev; 2001 Apr; 10(4):339-44. PubMed ID: 11319174
[TBL] [Abstract][Full Text] [Related]
10. Genistein and enterolactone in relation to Ki-67 expression and HER2 status in postmenopausal breast cancer patients.
Jaskulski S; Jung AY; Rudolph A; Johnson T; Thöne K; Herpel E; Sinn P; Chang-Claude J
Mol Nutr Food Res; 2017 Nov; 61(11):. PubMed ID: 28734033
[TBL] [Abstract][Full Text] [Related]
11. Serum enterolactone concentration is not associated with breast cancer risk in a nested case-control study.
Kilkkinen A; Virtamo J; Vartiainen E; Sankila R; Virtanen MJ; Adlercreutz H; Pietinen P
Int J Cancer; 2004 Jan; 108(2):277-80. PubMed ID: 14639615
[TBL] [Abstract][Full Text] [Related]
12. Circulating enterolactone and risk of breast cancer: a prospective study in New York.
Zeleniuch-Jacquotte A; Adlercreutz H; Shore RE; Koenig KL; Kato I; Arslan AA; Toniolo P
Br J Cancer; 2004 Jul; 91(1):99-105. PubMed ID: 15226762
[TBL] [Abstract][Full Text] [Related]
13. Serum enterolactone and postmenopausal breast cancer risk by estrogen, progesterone and herceptin 2 receptor status.
Zaineddin AK; Vrieling A; Buck K; Becker S; Linseisen J; Flesch-Janys D; Kaaks R; Chang-Claude J
Int J Cancer; 2012 Mar; 130(6):1401-10. PubMed ID: 21544804
[TBL] [Abstract][Full Text] [Related]
14. CYP17 gene polymorphism and its association with high-risk north Indian breast cancer patients.
Chakraborty A; Murthy NS; Chintamani C; Bhatnagar D; Mohil RS; Sharma PC; Saxena S
J Hum Genet; 2007; 52(2):159-165. PubMed ID: 17235448
[TBL] [Abstract][Full Text] [Related]
15. CYP17 genetic polymorphism, breast cancer, and breast cancer risk factors.
Ambrosone CB; Moysich KB; Furberg H; Freudenheim JL; Bowman ED; Ahmed S; Graham S; Vena JE; Shields PG
Breast Cancer Res; 2003; 5(2):R45-51. PubMed ID: 12631398
[TBL] [Abstract][Full Text] [Related]
16. The protective association of high plasma enterolactone with breast cancer is reasonably robust in women with polymorphisms in the estrogen receptor alpha and beta genes.
Sonestedt E; Ivarsson MI; Harlid S; Ericson U; Gullberg B; Carlson J; Olsson H; Adlercreutz H; Wirfält E
J Nutr; 2009 May; 139(5):993-1001. PubMed ID: 19321582
[TBL] [Abstract][Full Text] [Related]
17. Cyp17, urinary sex steroid levels and breast cancer risk in postmenopausal women.
Onland-Moret NC; van Gils CH; Roest M; Grobbee DE; Peeters PH
Cancer Epidemiol Biomarkers Prev; 2005 Apr; 14(4):815-20. PubMed ID: 15824149
[TBL] [Abstract][Full Text] [Related]
18. Polymorphisms in the CYP19 gene may affect the positive correlations between serum and urine phytoestrogen metabolites and plasma androgen concentrations in men.
Low YL; Taylor JI; Grace PB; Dowsett M; Folkerd E; Doody D; Dunning AM; Scollen S; Mulligan AA; Welch AA; Luben RN; Khaw KT; Day NE; Wareham NJ; Bingham SA
J Nutr; 2005 Nov; 135(11):2680-6. PubMed ID: 16251630
[TBL] [Abstract][Full Text] [Related]
19. Association between the T27C polymorphism in the cytochrome P450 c17alpha (CYP17) gene and risk factors for breast cancer.
Hong CC; Thompson HJ; Jiang C; Hammond GL; Tritchler D; Yaffe M; Boyd NF
Breast Cancer Res Treat; 2004 Dec; 88(3):217-30. PubMed ID: 15609124
[TBL] [Abstract][Full Text] [Related]
20. A polymorphism in CYP17 and endometrial cancer risk.
Haiman CA; Hankinson SE; Colditz GA; Hunter DJ; De Vivo I
Cancer Res; 2001 May; 61(10):3955-60. PubMed ID: 11358812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
